Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
出版年份 2022 全文链接
标题
Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-09-16
DOI
10.3389/fphar.2022.967317
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The HDAC2/SP1/miR-205 feedback loop contributes to tubular epithelial cell extracellular matrix production in diabetic kidney disease
- (2022) Zongji Zheng et al. CLINICAL SCIENCE
- Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review
- (2022) Slobodan M. Janković et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease
- (2022) Yaning Zheng et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
- (2022) Brendon L. Neuen et al. CIRCULATION
- Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease
- (2022) Edgar Lerma et al. POSTGRADUATE MEDICINE
- A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes
- (2021) Mengyue Lin et al. BLOOD PRESSURE
- US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States
- (2021) Kirsten L. Johansen et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease
- (2021) Pantelis Sarafidis et al. HYPERTENSION
- Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy
- (2021) Swayam Prakash Srivastava et al. Nature Communications
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
- (2021) Nina Vodošek Hojs et al. Pharmaceuticals
- Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
- (2021) Ulrich Kintscher et al. BRITISH JOURNAL OF PHARMACOLOGY
- Aldosterone Blockade in Acute Myocardial Infarction: A Systematic Review and Meta-Analysis
- (2021) Qiao Chen et al. Cardiovascular Therapeutics
- 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
- (2021) DIABETES CARE
- Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
- (2021) Jonatan Barrera-Chimal et al. Nature Reviews Nephrology
- The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
- (2021) Michele Provenzano et al. Kidney International Reports
- Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
- (2021) Peter Rossing et al. Kidney International Reports
- Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs
- (2020) Swayam Prakash Srivastava et al. Genes
- Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease
- (2020) Ningning Wan et al. JOURNAL OF HUMAN HYPERTENSION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone
- (2020) Juan Simon Rico-Mesa et al. Current Cardiology Reports
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- MicroRNAs in the Progress of Diabetic Nephropathy: A Systematic Review and Meta-Analysis
- (2019) Li-ping Wang et al. Evidence-based Complementary and Alternative Medicine
- Mineralocorticoid Antagonism and Diabetic Kidney Disease
- (2019) Yuliya Lytvyn et al. Current Diabetes Reports
- Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials
- (2019) Pingping Yang et al. HEART FAILURE REVIEWS
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney
- (2019) Swayam Prakash Srivastava et al. Frontiers in Pharmacology
- Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta‐analysis
- (2019) Chao Zuo et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure
- (2018) Hui Pei et al. MEDICINE
- MiR-4756 promotes albumin-induced renal tubular epithelial cell epithelial-to-mesenchymal transition and endoplasmic reticulum stress via targeting Sestrin2
- (2018) Yijie Jia et al. JOURNAL OF CELLULAR PHYSIOLOGY
- SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis
- (2018) Swayam Prakash Srivastava et al. Cell Death & Disease
- A meta-analysis of add-on use of spironolactone in patients with resistant hypertension
- (2017) Di Zhao et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy
- (2017) Shigehiro Katayama et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling
- (2017) Min Liu et al. Nature Communications
- Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials
- (2016) Jie V. Zhao et al. Journal of the American Society of Hypertension
- The coordinated roles of miR-26a and miR-30c in regulating TGFβ1-induced epithelial-to-mesenchymal transition in diabetic nephropathy
- (2016) Zongji Zheng et al. Scientific Reports
- Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis
- (2015) Jing Hou et al. CLINICAL THERAPEUTICS
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences
- (2015) Luz Lozano-Maneiro et al. Journal of Clinical Medicine
- Diabetic Kidney Disease: A Report From an ADA Consensus Conference
- (2014) Katherine R. Tuttle et al. DIABETES CARE
- Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy
- (2014) Xiaojie Wang et al. KIDNEY INTERNATIONAL
- Evaluation of spironolactone plus hydrochlorothiazide in reducing proteinuria in type 2 diabetic nephropathy
- (2013) Ali Momeni et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension
- (2012) Sunil Kumar Kota et al. International Journal of Diabetes in Developing Countries
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Central regulation of blood pressure by the mineralocorticoid receptor
- (2011) Elise P. Gomez-Sanchez et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes
- (2009) T. Ninomiya et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy
- (2009) U. F. Mehdi et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Change in Proteinuria After Adding Aldosterone Blockers to ACE Inhibitors or Angiotensin Receptor Blockers in CKD: A Systematic Review
- (2008) Andrew S. Bomback et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now